Vor Biopharma Inc
For the period ended Dec 31, 2023. Filed Mar 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 20, 2024
VOR$19.98+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| (in thousands, except share amounts) | 2023 | 2022 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $31,360 | $57,706 |
| Marketable securities | 105,815 | 172,539 |
| Prepaid expenses | 3,153 | 4,368 |
| Other current assets | 475 | 2,337 |
| Total current assets | 140,803 | 236,950 |
| Restricted cash equivalents | 2,413 | 2,413 |
| Property and equipment, net | 10,050 | 12,634 |
| Operating lease right-of-use assets | 40,048 | 44,444 |
| Other assets | 4,812 | 2,925 |
| Total assets | $198,126 | $299,366 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $815 | $1,772 |
| Accrued liabilities | 10,877 | 7,889 |
| Operating lease liabilities | 3,830 | 3,272 |
| Other current liabilities | 50 | 186 |
| Total current liabilities | 15,572 | 13,119 |
| Long-term liabilities: | ||
| Operating lease liabilities—non-current | 31,830 | 35,640 |
| Total liabilities | 47,402 | 48,759 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022 | — | — |
| Common stock, $0.0001 par value; 400,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 67,901,610, and 66,079,597 shares issued and 67,891,311 and 65,996,138 outstanding as of December 31, 2023 and December 31, 2022, respectively | 7 | 7 |
| Additional paid-in capital | 490,874 | 473,587 |
| Accumulated other comprehensive loss | (77) | (770) |
| Accumulated deficit | (340,080) | (222,217) |
| Total stockholders’ equity | 150,724 | 250,607 |
| Total liabilities and stockholders’ equity | $198,126 | $299,366 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.